CDNA · Company research
CareDx, Inc. (CDNA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| CareDx's results call is set for 1:30 p.m. PT, with a live webcast. - Stock Titan | CareDx's results call is set for 1:30 p.m. PT, with a live webcast. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| CareDx Inc (CDNA) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 64/100 - GuruFocus | CareDx Inc (CDNA) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 64/100 GuruFocus | View source ↗ | GuruFocus | Oct 13, 2026 | neutral | 0 | 0.6 |
| CareDx, Inc (CDNA) stock price, news, quote and history - Yahoo Finance UK | CareDx, Inc (CDNA) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 11, 2026 | neutral | 0 | 0.6 |
| Did Reimbursement Tailwinds Just Shift CareDx (CDNA) Stock Narrative? - Simply Wall Street | Did Reimbursement Tailwinds Just Shift CareDx (CDNA) Stock Narrative? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| CareDx, Inc. (CDNA) stock price, news, quote and history - Yahoo Finance Singapore | CareDx, Inc. (CDNA) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 10, 2026 | neutral | 0 | 0.6 |
| CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target Changes - Yahoo Finance | CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target Changes Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| CareDx (CDNA) Stock May Be 30% Below Fair Value On Fresh $74 Target - Simply Wall Street | CareDx (CDNA) Stock May Be 30% Below Fair Value On Fresh $74 Target Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| CareDx Inc (CDNA) Shares Fall 8.7% -- What GF Score of 64 Tells Investors - GuruFocus | CareDx Inc (CDNA) Shares Fall 8.7% -- What GF Score of 64 Tells Investors GuruFocus | View source ↗ | GuruFocus | Oct 6, 2026 | neutral | 0 | 0.6 |
| CareDx slides as rally cools with no fresh company catalyst evident - Quiver Quantitative | CareDx slides as rally cools with no fresh company catalyst evident Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.50 v - GuruFocus | A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.50 v GuruFocus | View source ↗ | GuruFocus | Oct 6, 2026 | neutral | 0 | 0.6 |
| Stock vesting triggers 997-share tax withholding for CareDx (CDNA) counsel Jeffrey Adam Novack. - Stock Titan | Stock vesting triggers 997-share tax withholding for CareDx (CDNA) counsel Jeffrey Adam Novack. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| For stock-vesting taxes, CareDx (CDNA) withholds 2,619 shares from its chief commercial officer. - Stock Titan | For stock-vesting taxes, CareDx (CDNA) withholds 2,619 shares from its chief commercial officer. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR | The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Tax withholding leaves CareDx (CDNA) CFO Keith Kennedy with 208,686 directly held shares. - Stock Titan | Tax withholding leaves CareDx (CDNA) CFO Keith Kennedy with 208,686 directly held shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| CareDx (CDNA) Stock Could Be 33% Below Fair Value On Cash Flow - Simply Wall Street | CareDx (CDNA) Stock Could Be 33% Below Fair Value On Cash Flow Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? - Yahoo Finance | CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade) - Seeking Alpha | CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 25, 2026 | neutral | 0 | 0.6 |
| Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently - Benzinga | Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently Benzinga | View source ↗ | Benzinga | Sep 23, 2026 | neutral | 0 | 0.6 |
| CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Case - ChartMill | CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Case ChartMill | View source ↗ | ChartMill | Sep 19, 2026 | neutral | 0 | 0.6 |
| CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen - ChartMill | CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen ChartMill | View source ↗ | ChartMill | Aug 28, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.